Jean-Christophe BERNHARD (0000-0001-8564-1699)

Personal information

Biography

Professor Bernhard is involved in international training and had collaborations with multiple institutes, including Hospital San Pau in Barcelona, Spain, The Hillman Cancer Center in Pittsburgh, USA and The Norris Cancer Center – Institute of Urology in Los Angeles, USA. He is also affiliated with the Research Unit BRIC-U1312 of the National Institute of Health and Medical Research (INSERM).

He is the coordinator of the National databank and French research network on Kidney Cancer UroCCR (www.uroccr.fr), certified by the French National Institute of Cancer (INCa), a board-member of the Cancer Committee of the French Association of Urology (CCAFU), a member of the scientific group of the European Robotic Urology Section of the EAU (ERUS) and an associate member of the EAU Section of Oncological Urology (ESOU).

His research areas of interest include conservative robotic kidney cancer surgery, virtual navigation, 3D pre-operative models for surgical planning and simulation, AI, Telehealth and biomarkers.
Coordinator of the Research & Innovation Program on kidney cancer - I.CaRe Bordeaux.
Coordinator of the RHU program Digital Urology 3D (France 2030, www.digital-urology-3d.fr)
Coordinator of the Digital & Personalized Recovery in Urology project (DiPRU) (France 2030, BPI France)
Medical Director of the Robotic Training Center of Bordeaux University.
Leader of the emerging Kidney Cancer team (I.CaRe) of the Inserm U1312 unit BRIC (BoRdeaux Institute of OnCology) (https://www.bricbordeaux.com/en/bric-team/equipe-emergente-i-care-programme-integre-de-recherche-innovation-sur-le-cancer-du-rein/)
Coordinator of the Fund for Research & Innovation in kidney surgery (www.chirurgie-renale-bordeaux.fr)

He is coauthor of over 195 international publications https://www.ncbi.nlm.nih.gov/pubmed/?term=bernhard+JC

Activities

Collapse all

Centre Hospitalier Universitaire de Bordeaux: Bordeaux, Aquitaine, FR

2017-09-01 to present | Professeur (Urologie)

Employment

Jean-Christophe BERNHARD

https://orcid.org/0000-0001-8564-1699

Personal information

Websites & social links

Other IDs

Keywords

Countries

Biography

Activities

Employment (1)

Centre Hospitalier Universitaire de Bordeaux: Bordeaux, Aquitaine, FR

Funding (2)

Clinical and biological national multidisciplinary database for Kidney Cancer : UroCCR

Study and interest of CXCL4, CXCL4L1 and CXCR3 in clear cell Renal Cell Carcinoma.

Works (50 of 155)

A CT-Based Clinical, Radiological and Radiomic Machine Learning Model for Predicting Malignancy of Solid Renal Tumors (UroCCR-75)

Combinations of Anti-Angiogenic Agents and Immune Checkpoint Inhibitors in Renal Cell Carcinoma: Best Option?

Implementing HoLEP in an Academic Department With Multiple Surgeons in Training: Mentoring Is the Key for Success

Therapeutic Management of Metastatic Clear Cell Renal Cell Carcinoma: A Revolution in Every Decade

Feasibility of robotic-assisted partial nephrectomy for complete remission of metastatic renal cell carcinoma after long exposure to immune checkpoint inhibitors (UroCCR-106)

Can Pre-Operative Neutrophil-to-Lymphocyte Ratio (NLR) Help Predict Non-Metastatic Renal Carcinoma Recurrence after Nephrectomy? (UroCCR-61 Study)

French AFU Cancer Committee Guidelines - Update 2022-2024: management of kidney cancer

Day-case robotic-assisted partial nephrectomy: feasibility and preliminary results of a prospective evaluation (UroCCR-25 AMBU-REIN study)

Nurse-led coordinated surgical care pathways for cost optimization of robotic-assisted partial nephrectomy: medico-economic analysis of the UroCCR-25 AMBU-REIN study

Thyroid‐like follicular renal cell carcinoma with sarcomatoid differentiation and an aggressive clinical course: a case report confirming the presence of the EWSR1::PATZ1 fusion gene

Denoised VEGFR2 expression relates to sunitinib efficacy in advanced Clear Cell Renal Cell Carcinoma

Diagnostic and interventional radiology is a milestone in the management of renal tumors in Birt-Hugg-Dubé syndrome.

A preoperative nomogram to predict major complications after robot assisted partial nephrectomy (UroCCR-57 study).

[The basis of endoscopic stones recognition, a prospective monocentric study].

Measurement of the Accuracy of 3D-Printed Medical Models to Be Used for Robot-Assisted Partial Nephrectomy.

Long-term oncological outcomes of cystic renal cell carcinoma according to the Bosniak classification.

Who is dying after nephrectomy for cancer? Study of risk factors and causes of death after analyzing morbidity and mortality reviews (UroCCR-33 study).

Outcomes after salvage radical prostatectomy and first-line radiation therapy or HIFU for recurrent localized prostate cancer: results from a multicenter study.

Metastatic Clear-cell Renal Cell Carcinoma With a Long-term Response to Sunitinib: A Distinct Phenotype Independently Associated With Low PD-L1 Expression.

Evaluation of axitinib to downstage cT2a renal tumours and allow partial nephrectomy: a phase II study.

[French ccAFU guidelines - Update 2018-2020: Management of kidney cancer].

[Partial nephrectomy for renal masses >7cm: Morbidity, oncological and functional outcomes (UroCCR-7 study)].

Sunitinib Alone or after Nephrectomy in Metastatic Renal-Cell Carcinoma.

Contemporary assessment of the correlation between Bosniak classification and histological characteristics of surgically removed atypical renal cysts (UroCCR-12 study).

Erratum to "In vivo percutaneous microwave ablation in kidneys: Correlation with ex vivo data and ablation work" [Diagn. Interv. Imaging 99 (1) (2018) 3-8].

Impact of hospital volume and surgeon volume on robot-assisted partial nephrectomy outcomes: a multicentre study.

Overall survival and oncological outcomes after partial nephrectomy and radical nephrectomy for cT2a renal tumors: A collaborative international study from the French kidney cancer research network UroCCR.

Soluble CD146 is a predictive marker of pejorative evolution and of sunitinib efficacy in clear cell renal cell carcinoma.

In vivo percutaneous microwave ablation in kidneys: Correlation with ex vivo data and ablation work.

T2 Star-weighted Angiography (SWAN) Allows to Concomitantly Assess the Prostate Contour While Detecting Fiducials Before MR-based Intensity-modulated Radiation Therapy in Prostate Carcinoma.

Total Preperitoneal Robot-Assisted Kidney Transplantation.

Deletion of the transcription factor SOX4 is implicated in syndromic nephroblastoma.

Hilar fat infiltration: A new prognostic factor in metastatic clear cell renal cell carcinoma with first-line sunitinib treatment.

Influence du score de Gleason des marges chirurgicales de prostatectomie totale sur la récidive biologique.

Day-Case Holmium Laser Enucleation of the Prostate: Prospective Evaluation of 90 Consecutive Cases.

Percutaneous image-guided biopsies of small renal tumors: Current practice and perspectives.

Correlation of c-MET Expression with PD-L1 Expression in Metastatic Clear Cell Renal Cell Carcinoma Treated by Sunitinib First-Line Therapy.

Metastatic chromophobe renal cell carcinoma treated with targeted therapies: A Renal Cross Channel Group study.

Pulmonary arterial hypertension due to an intratumoral shunt: an unexpected side effect of sunitinib.

[Impact of the Jardé's law on research management].

Microwave ablation of renal tumors: A narrative review of technical considerations and clinical results.

Off-Clamp versus On-Clamp Robotic Partial Nephrectomy: A Multicenter Match-Paired Case-Control Study.

Partial nephrectomy versus ablative therapy for the treatment of renal tumors in an imperative setting.

CT and MR imaging features of mucinous tubular and spindle cell carcinoma of the kidneys. A multi-institutional review.

Sunitinib Stimulates Expression of VEGFC by Tumor Cells and Promotes Lymphangiogenesis in Clear Cell Renal Cell Carcinomas.

Is Multiparametric MRI Useful for Differentiating Oncocytomas From Chromophobe Renal Cell Carcinomas?

Localized chromophobe carcinomas treated by nephron-sparing surgery have excellent oncologic outcomes.

Comparison of 1800 Robotic and Open Partial Nephrectomies for Renal Tumors.

[CCAFU french national guidelines 2016-2018 on renal cancer].

La localisation tumorale sinusale massive ne compromet pas la réalisation d’une tumorectomie robot-assistée.

Peer review (1 review for 1 publication/grant)